Product Information
CITALOPRAM HBR 10 MG TABLET is a generic product labeled by Exelan Pharmaceuticals Inc., priced at $0.0260 per EA under NDC 76282062890. Its NADAC has been published 242 times since Feb 16, 2022.
FDA first approved this application on Oct 3, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/1
Manufacturer
Exelan Pharmaceuticals Inc.NDC
76282062890
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CITALOPRAM HYDROBROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077534FDA Approved
10/3/2006
TE Code
AB
On Market Since
11/10/2017
Pharmacological Classes
Price Statistics
The NADAC for CITALOPRAM HBR 10 MG TABLET has been published 242 times since Feb 16, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0260 per EA |
|---|---|
| All-time high | $0.0285 (Jul 12, 2023) |
| All-time low | $0.0204 (May 22, 2024) |
| 52-week high | $0.0260 |
| 52-week low | $0.0240 |
| Median price | $0.0254 |
| Average price | $0.0252 |
| Largest weekly change | +24.2% (Jun 19, 2024) |
| Weeks tracked | 242 |
| Tracking since | Feb 16, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Exelan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CITALOPRAM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CITALOPRAM HBR 10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CITALOPRAM HBR 10 MG TABLET, manufactured by Exelan Pharmaceuticals Inc., is $0.0260 per EA (NDC 76282062890), effective Sep 30, 2026.
How has the price of CITALOPRAM HBR 10 MG TABLET changed over time?
Over the history we have for it, the NADAC for CITALOPRAM HBR 10 MG TABLET has held within roughly two percent of its current level. It has been tracked across 242 weekly CMS publications since Feb 16, 2022.
What are the highest and lowest recorded NADAC prices for CITALOPRAM HBR 10 MG TABLET?
Since Feb 16, 2022, the NADAC for CITALOPRAM HBR 10 MG TABLET has ranged from a low of $0.0204 (May 22, 2024) to a high of $0.0285 (Jul 12, 2023), with a median of $0.0254 per EA.
Are there cheaper alternatives to CITALOPRAM HBR 10 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CITALOPRAM HBR 10 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CITALOPRAM HBR 10 MG TABLET?
CITALOPRAM HBR 10 MG TABLET (NDC 76282062890) is labeled by Exelan Pharmaceuticals Inc., and CMS classifies it as a generic product.